Clinical trials: Sodium-glucose Co-transporter-2 Inhibitors
Diabetes Mellitus, Type 2, Arterial Hypertension
Antidiuretic Function Before and During Treatment With SGLT2 Inhibitors
Subjects treated with Canagliflozin, Dapagliflozin and Empagliflozin obtained improvement on blood pressure values, body weight and cardiovascular mortality but pathophysiological explanations of these effects are not yet known.
- Conditions
- Diabetes Mellitus, Type 2, Arterial Hypertension, Body Weight Changes
- Trial name
- GliRACo1 (NCT03917758)
- Testing
- SGLT2 inhibitor
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- University of Turin, Italy
Peritoneal Dialysis Complication, Renal Function Aggravated
Dapagliflozin Delays the Loss of Renal Function in Peritoneal Dialysis Patients
This study aims to explore the role of dagliflozin in preserving the residual renal function(RRF) in peritoneal dialysis (PD) patients.
- Conditions
- Peritoneal Dialysis Complication, Renal Function Aggravated, Sodium-glucose Co-transporter-2 Inhibitors
- Trial name
- NCT06398977
- Testing
- Dapagliflozin
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Sichuan Academy of Medical Sciences
Diabetes Mellitus, Type 2, Cognitive Functions Confusion
Effects of SGLT2i on the Cognitive Function in T2DM Patient (ESCDP)
Type 2 diabetes is associated with diabetic cognopathy, the prevalence of Alzheimer's Disease(AD) in T2DM patients is 1.5 to 2.5 times higher than the general population.
- Trial name
- ESCDP (NCT04304261)
- Testing
- Canagliflozin, Sitagliptin
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Third Military Medical University
Heart Failure with Reduced Ejection Fraction, End Stage Renal Disease on Dialysis
Empagliflozin in Heart Failure with Reduced Ejection Fraction and End Stage Renal Disease
In patients with ESRD, up to 20% of patients suffer from HFrEF, leading to significant CV morbidity and mortality. Several drug classes that provide survival benefits for patients with HFrEF, including SGLT2i, lack data regarding…
- Trial name
- EMPA-RRED (NCT06249932)
- Testing
- Empagliflozin 25 MG
- Where
- 2 sites in Taiwan
- Volunteers
- 95 people
- Sponsor
- National Taiwan University Hospital
Acute Decompensated Heart Failure
The Hemodynamic Effects of SGLT2i in Acute Decompensated Heart Failure
The main purpose of this study is to observe hemodynamic effects of initiating sodium-glucose co-transporter 2 inhibitors (SGLT2i) in patients admitted to the intensive care unit (ICU) with acute decompensated heart failure.
- Trial name
- NCT05346653
- Testing
- SGLT2i, No SGLT2i
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Chicago
Left Cardiac Catheterization, Percutaneous Coronary Intervention
Dapagliflozin to Prevent the Incidence of Contrast Induced Nephropathy After Heart Catheterization and Percutaneous Coronary Intervention
Left heart catheterization and percutaneous coronary intervention (PCI) has become a useful tool in interventional cardiology, in which iodinated contrast media is used.
- Conditions
- Left Cardiac Catheterization, Percutaneous Coronary Intervention, Acute Kidney Injury, Sodium-glucose Co-transporter 2 Inhibitors
- Trial name
- NCT04806633
- Testing
- Dapagliflozin 5mg
- Where
- 2 sites in Greece
- Volunteers
- 1,722 people
- Sponsor
- G.Gennimatas General Hospital
Sodium Glucose Co-Transporter 2 Inhibitors, Estimated Glomerular Filtration Rate
Sodium Glucose Co-Transporter 2 Inhibitors on Estimated Glomerular Filtration Rate in Diabetic Versus Non-Diabetic Chronic Kidney Disease Patients
The work aimed to compare the effects of Sodium-glucose co-transporter-2 (SGLT2) inhibitors on glomerular filtration rate (GFR) in patients with diabetic chronic kidney disease (CKD) and non-diabetic CKD.
- Conditions
- Sodium Glucose Co-Transporter 2 Inhibitors, Estimated Glomerular Filtration Rate, Diabetes, Chronic Kidney Disease
- Trial name
- NCT07302464
- Testing
- Sodium Glucose Co-Transporter 2 Inhibitors
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Ain Shams University
Sepsis, Septic Shock
Impact of Prior SGLT2 Inhibitors Use on the Development and Progression of Sepsis-Associated Acute Kidney Injury
The primary objective of this study is to investigate whether using SGLT2i may be associated with decreased incidence of sepsis-induced AKI or not.
- Conditions
- Sepsis, Septic Shock, Acute Kidney Injury
- Trial name
- NCT06902493
- Testing
- No intervention
- Where
- Saudi Arabia
- Volunteers
- 664 people
- Sponsor
- University of Jazan
Heart Failure, Sleep Disordered Breathing
SGLT2-Inhibitors for Sleep Apnea in Heart Failure
Heart Failure is a disease involving many different aspects of the human body, including changes in metabolism, the way the body produces and uses energy.
- Trial name
- NCT04640493
- Testing
- Dapagliflozin, WatchPat
- Where
- United States
- Sponsor
- Columbia University
Type2diabetes
Effect of SGLT-2 Inhibitors in Patients With T2DM and Moderate to Severe Liver Fibrosis
This retrospective study will be of 12 months duration where 40 T2DM patients coming to FORTIS C-DOC hospital in OPD with F3 fibrosis will be included in the study.
- Trial name
- NCT05943899
- Where
- India
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Diabetes Foundation, India
Chronic Kidney Diseases, Bone Diseases, Metabolic
Effect of Dapagliflozin on Renal Outcomes and Bone Mineral Disease in Non-diabetic Chronic Kidney Disease Patients
It is a randomized controlled trial in which 100 non diabetic chronic kidney disease (CKD) patient is being participated. Their estimated glomerular filtration rate (eGFR) between 25-75 ml/min/1.73 m2.
- Trial name
- NCT05735197
- Testing
- Dapagliflozin 10mg Tab
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Mansoura University
Diabetic Foot Ulcer
SGLT-i Use in Diabetic Foot Ulcer Disease
Background: People with diabetes and either current or previous diabetic foot ulcer disease (DFUD) are at very high risk for adverse cardiovascular events including heart attacks and strokes.
- Trial name
- NCT06000722
- Testing
- eDelphi method
- Where
- United Kingdom
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- University of Leicester
Chronic Heart Failure With Reduced Systolic Function
Dapagliflozin Effect on Symptoms and Biomarkers in Patients With Heart Failure
The primary purpose of this study is to evaluate the impact of dapagliflozin, as compared with placebo, on heart failure disease-specific biomarkers, symptoms, health status, and quality of life in patients with chronic heart…
- Trial name
- DEFINE-HF (NCT02653482)
- Testing
- Dapagliflozin
- Where
- 25 sites in United States
- Volunteers
- 263 people
- Sponsor
- Saint Luke's Health System
Type 1 Diabetes Mellitus With Diabetic Nephropathy
dApagliflozin SC0062 and Prevention of Renal Injury; a Randomized Evaluation
The aim of this study is to test the hypothesis that dapagliflozin (SGLT2 inhibitor) and SC0062 (ERA) combination therapy augments nephroprotection and mitigates fluid retention and ketogenesis in people with T1D through…
- Trial name
- ASPIRE-1 (NCT06072326)
- Testing
- Dapagliflozin (Forxiga®), SC0062 strength 10mg, SC0062 and dapagliflozin
- Where
- 5 sites in Denmark, Finland
- Volunteers
- 36 people
- Sponsor
- University Medical Center Groningen
Diabetic Nephropathy Type 2
Comparison Between the Efficacy of SGLT2 Inhibitor Therapy Versus ACE Inhibitor in the Treatment of Diabetic Kidney Disease
Diabetes is the leading cause of chronic kidney disease (CKD) and end-stage kidney disease worldwide. Diabetic kidney disease (DKD) is a clinical diagnosis based upon the presence of reduced glomerular filtration rate (GFR)…
- Trial name
- SGLT2i VS ACEi (NCT05373004)
- Testing
- Empagliflozin 25 MG, Enalapril Maleate 20 mg
- Volunteers
- 212 people
- Sponsor
- Omar Tarek Elfarargi
Peritoneal Dialysis Complication, End Stage Kidney Disease
meChANisms and sAfety of SGLT2 Inhibition in peRitoneal dialYsis
The primary aim of this study is to determine the safety and mechanisms of SGLT2 inhibition in individuals on peritoneal dialysis (PD) with residual kidney function (RKF).
- Conditions
- Peritoneal Dialysis Complication, End Stage Kidney Disease, Sodium-glucose Co-transporter-2 Inhibitors, Kidney Dysfunction
- Trial name
- CANARY (NCT05715814)
- Testing
- Empagliflozin 25 MG
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- University Health Network, Toronto
Diabetes Mellitus, Type 2
To Assess the Risk of Acute Pancreatitis in Patients With Type 2 Diabetes Mellitus Treated With Empagliflozin
To compare the risk of acute pancreatitis in patients with Type 2 diabetes mellitus (T2DM) newly initiating empagliflozin to that of patients newly initiating other oral non-incretin/non-Sodium glucose co-transporter-2 inhibitor…
- Trial name
- NCT05162014
- Testing
- empagliflozin, Oral non-incretin/non-sodium glucose co-transporter-2 inhibitors (SGLT2)-containing hypoglycaemic agents
- Where
- Germany
- Volunteers
- 494,679 people
- Sponsor
- Boehringer Ingelheim
Chronic Kidney Disease (Mild to Moderate), Albuminuria
Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Adolescents With Early Stages of Chronic Kidney Disease
Chronic kidney disease (CKD) is highly prevalent in the state of Aguascalientes, Mexico, particularly among adolescents and young adults.
- Conditions
- Chronic Kidney Disease (Mild to Moderate), Albuminuria, Adolescent, Sodium Glucose Co-Transporter 2 Inhibitors
- Trial name
- IECA-MEX (NCT07405216)
- Testing
- Dapagliflozin (10mg Tab)
- Where
- Mexico
- Volunteers
- 200 people
- Sponsor
- Centenario Hospital Miguel Hidalgo
Heart Failure, Type 2 Diabetes Mellitus
SGLT2 Inhibition in Combination With Diuretics in Heart Failure
The RECEDE-CHF trial is a single centre phase IV, randomised, double-blind, placebo-controlled, crossover trial conducted in NHS Tayside, Scotland comparing empagliflozin 25mg, to placebo in patients with Type 2 Diabetes and mild…
- Trial name
- RECEDE-CHF (NCT03226457)
- Testing
- Empagliflozin 25mg, Frusemide
- Where
- United Kingdom
- Volunteers
- 23 people
- Sponsor
- University of Dundee
Acute Decompensated Heart Failure
Pharmacokinetics of Bisoprolol and SGLT2i in Acutely Decompensated Heart Failure
The pharmacokinetics (PK) and pharmacodynamics (PD) of bisoprolol and sodium-glucose co-transporter-2 inhibitors (SGLT2i, dapagliflozin and empagliflozin) in patients with acutely decompensated heart failure (ADHF), compared to…
- Trial name
- BISO-ADHF (NCT06453577)
- Testing
- Recompensation (guideline directed medical therapy)
- Where
- Germany
- Volunteers
- 33 people
- Sponsor
- Universität des Saarlandes